Review in Biotech (Basel (Switzerland)), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors.
Mengya LiuDepartment of Cellular and Molecular Anatomy, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-Ku, Hamamatsu 431-3192, Shizuoka, Japan.
Chi ZhangDepartment of Cellular and Molecular Anatomy, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-Ku, Hamamatsu 431-3192, Shizuoka, Japan.ORCID 0000-0002-8889-2044
Lili XuDepartment of Cellular and Molecular Anatomy, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-Ku, Hamamatsu 431-3192, Shizuoka, Japan.ORCID 0000-0001-5340-8841
Md Muedur RahmanDepartment of Cellular and Molecular Anatomy, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-Ku, Hamamatsu 431-3192, Shizuoka, Japan.ORCID 0000-0001-9894-9182
Shoshiro HirayamaDepartment of Cellular and Molecular Anatomy, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-Ku, Hamamatsu 431-3192, Shizuoka, Japan.
Shuhei AramakiDepartment of Cellular and Molecular Anatomy, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-Ku, Hamamatsu 431-3192, Shizuoka, Japan.ORCID 0000-0001-5842-6176
Atsushi BabaDepartment of Cellular and Molecular Anatomy, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-Ku, Hamamatsu 431-3192, Shizuoka, Japan.ORCID 0000-0002-6871-7249
Ryo OmagariDepartment of Cellular and Molecular Anatomy, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-Ku, Hamamatsu 431-3192, Shizuoka, Japan.
Yutaka TakahashiDepartment of Cellular and Molecular Anatomy, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-Ku, Hamamatsu 431-3192, Shizuoka, Japan.
Tomoaki KahyoDepartment of Cellular and Molecular Anatomy, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-Ku, Hamamatsu 431-3192, Shizuoka, Japan.ORCID 0000-0002-2205-5665
Mitsutoshi SetouDepartment of Cellular and Molecular Anatomy, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-Ku, Hamamatsu 431-3192, Shizuoka, Japan.ORCID 0000-0002-1302-6467
Funding
Grant-in-Aid for Early-Career Scientists 25K18699Grant-in-Aid for Scientific Research(B) JP22H02793Grant-in-Aid for Scientific Research(C) 24K09982Japan Agency for Medical Research and Development 21ak0101179Japan Agency for Medical Research and Development JP24tm0524001Japan Agency for Medical Research and Development JP24zf0127012Japan Agency for Medical Research and Development JP25jf0126014JSPS KAKENHI JP23K18197MEXT Project for promoting public utilization of advanced research infrastructure(Imaging Platform) JPMXS0450200225the Fujita Mind-Brain Research & Innovation Center for Drug Generation (Fujita Mind-BRIDGe) of the Japan's Peak Research Universities (J-PEAKS) Program funded by the Japan Society for the Promotion of Science (JSPS) N/A
6 · The paper itself
Abstract
Mass spectrometry imaging (MSI) visualizes the spatial distribution of biomolecules in tissues, whereas ion mobility-mass spectrometry (IM-MS) separates ions through the collision cross-section (CCS) with an inert gas, providing the structural characteristics of isomers. Recent advances have established an integrated workflow, ion mobility-mass spectrometry imaging (IM-MSI), that couples IM with MSI, uniting molecular discrimination with spatial mapping. This synergy has been widely applied in oncology and neuropsychiatric disorders, offering unprecedented insights into biomarker discovery and disease mechanisms. Here, we summarize the principles and classifications of IM-MSI, review their combined biomedical applications, and discuss data processing workflows and commonly used tools.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Ion Mobility-Mass Spectrometry Imaging: Advances in Biomedical Research. · full record | OpenQuestion